Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOTS-AD: Optimal Treatment Sequences in Anxious Depression
NCT04245748Phase 4Recruiting
- Sponsor
- University of Cincinnati
- Start
- Mar 2020
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of escitalopram, duloxetine, clonazepam and pregabalin in mixed anxiety and depressive disorder (MADD), generalized anxiety disorder (GAD), Social Anxiety Disorder (SAD) and 2 more (2 arms), sponsored by University of Cincinnati. Primary endpoints: Hamilton Anxiety Rating at 20 weeks and Clinical Global Impression of Severity at 20 weeks. Started Mar 2020; status: recruiting.
02
Drugs
escitalopramduloxetineclonazepampregabalin
03
Conditions
mixed anxiety and depressive disorder (MADD)generalized anxiety disorder (GAD)Social Anxiety Disorder (SAD)separation anxiety disorder (SAD)panic disorder
Beyond the preview
Go deeper on NCT04245748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04245748.